Cullinan Management (CGEM) Stock Forecast & Price Target

Compare

202 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CGEM Analyst Ratings

Strong Buy

11 Buy

0 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Cullinan

Management

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CGEM Stock 12 Month Forecast

Average Price Target

$26.33

▲(243.29% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Cullinan Management in the last 3 months. The average price target is $26.33 with a high forecast of $34.00 and a low forecast of $22.00. The average price target represents a 243.29% change from the last price of $7.67.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","35":"$35","13.25":"$13.25","20.5":"$20.5","27.75":"$27.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,13.25,20.5,27.75,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.67,9.695384615384615,11.72076923076923,13.746153846153845,15.77153846153846,17.796923076923076,19.82230769230769,21.847692307692306,23.873076923076923,25.89846153846154,27.92384615384615,29.949230769230766,31.974615384615383,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.67,9.105384615384615,10.54076923076923,11.976153846153846,13.41153846153846,14.846923076923076,16.28230769230769,17.717692307692303,19.15307692307692,20.588461538461537,22.02384615384615,23.459230769230764,24.894615384615378,{"y":26.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.67,8.772307692307692,9.874615384615385,10.976923076923077,12.079230769230769,13.18153846153846,14.283846153846152,15.386153846153846,16.488461538461536,17.59076923076923,18.693076923076923,19.795384615384613,20.897692307692306,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.5,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.76,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.6,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.76,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.78,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.18,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.56,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$34.00

Average Price Target$26.33

Lowest Price Target$22.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Robert Burns

H.C. Wainwright

$24

Buy

212.91%

Upside

Initiated

08/21/25

Promising Developments in Cullinan Management's Cancer Treatment Pipeline Drive Buy RatingValuation and Risks. We assess Cullinan using a discounted cash flow (DCF)-based valuation methodology, with a 70% probability of launch for zipalertinib in exon 20+ NSCLC and a 20% probability of launch for CLN-978 in SLE. In addition, we employ an 11% discount rate, a 29% effective tax rate, and a 1.0% terminal growth rate. These assumptions yield a price objective of $24 per share, assuming 59.4M shares outstanding as of mid-2026.

Sean Laaman

Morgan Stanley

$35→$28

Buy

265.06%

Upside

Reiterated

08/18/25

Morgan Stanley Sticks to Their Buy Rating for Cullinan Management (CGEM)

David Dai

UBS

$24

Buy

212.91%

Upside

Reiterated

08/18/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cullinan Management (NASDAQ: CGEM), Recursion Pharmaceuticals (NASDAQ: RXRX) and Cochlear (Other OTC: CHEOF)

Kaveri Pohlman

Clear Street

$22

Buy

186.83%

Upside

Reiterated

08/08/25

Cullinan Management (CGEM) Gets a Buy from Clear Street

Soumit Roy

JonesTrading

$34

Buy

343.29%

Upside

Reiterated

08/08/25

Promising Pipeline Developments and Strategic Collaborations Drive Buy Rating for Cullinan ManagementWe aren't sure if cohort 3 (30μg) data will be available in 4Q25. Also, we are not sure if data will be presented at the ACR conf (Oct 24-29) or separately in a press release later in the year.

Julian Harrison

BTIG

$32

Buy

317.21%

Upside

Reiterated

08/07/25

Cullinan Management (CGEM) Receives a Buy from BTIG

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

08/07/25

Cullinan Management: Strong Financials and Promising Pipeline Justify Buy Rating

Andrew Berens

Leerink Partners

$28

Buy

265.06%

Upside

Reiterated

08/07/25

Analysts Offer Insights on Healthcare Companies: PepGen Inc. (NASDAQ: PEPG), Cullinan Management (NASDAQ: CGEM) and aTyr Pharma (NASDAQ: ATYR)We think this catalyst has the potential to surprise to the upside given the relatively low expectations, and based on management's enthusiasm when we spoke with them today. Velinotamig (BCMAxCD3 TCE), incensed from Genrix Bio (Not Rated) who retained rights in China, will enter Phase 1 in autoimmune diseases in China by YE25. Zipalertinib (EGFR Exon20) will have updated efficacy data from REZILIENT1 in NSCLC Exon20 patients previously treated with amivantamab at WCLC 2025 (Sept 6-9th). This dataset was last presented at ASCO 2025, where the ORR was 30% and the mDOR was 14.7 mo in patients treated with prior amivantamab.

Matt Phipps

William Blair

―

Buy

―

Reiterated

08/07/25

William Blair Sticks to Its Buy Rating for Cullinan Management (CGEM)

Alex Thompson CFA

Stifel Nicolaus

$22

Buy

186.83%

Upside

Initiated

06/11/25

Cullinan Therapeutics resumed with a Buy at StifelCullinan Therapeutics resumed with a Buy at Stifel

Robert Driscoll

Wedbush

$23

Buy

199.87%

Upside

Reiterated

06/05/25

Cullinan Management (CGEM) Receives a Buy from Wedbush

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Robert Burns

H.C. Wainwright

$24

Buy

212.91%

Upside

Initiated

08/21/25

Sean Laaman

Morgan Stanley

$35→$28

Buy

265.06%

Upside

Reiterated

08/18/25

Morgan Stanley Sticks to Their Buy Rating for Cullinan Management (CGEM)

David Dai

UBS

$24

Buy

212.91%

Upside

Reiterated

08/18/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cullinan Management (NASDAQ: CGEM), Recursion Pharmaceuticals (NASDAQ: RXRX) and Cochlear (Other OTC: CHEOF)

Kaveri Pohlman

Clear Street

$22

Buy

186.83%

Upside

Reiterated

08/08/25

Cullinan Management (CGEM) Gets a Buy from Clear Street

Soumit Roy

JonesTrading

$34

Buy

343.29%

Upside

Reiterated

08/08/25

Julian Harrison

BTIG

$32

Buy

317.21%

Upside

Reiterated

08/07/25

Cullinan Management (CGEM) Receives a Buy from BTIG

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

08/07/25

Cullinan Management: Strong Financials and Promising Pipeline Justify Buy Rating

Andrew Berens

Leerink Partners

$28

Buy

265.06%

Upside

Reiterated

08/07/25

Matt Phipps

William Blair

―

Buy

―

Reiterated

08/07/25

William Blair Sticks to Its Buy Rating for Cullinan Management (CGEM)

Alex Thompson CFA

Stifel Nicolaus

$22

Buy

186.83%

Upside

Initiated

06/11/25

Cullinan Therapeutics resumed with a Buy at StifelCullinan Therapeutics resumed with a Buy at Stifel

Robert Driscoll

Wedbush

$23

Buy

199.87%

Upside

Reiterated

06/05/25

Cullinan Management (CGEM) Receives a Buy from Wedbush

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cullinan Management

1 Month

xxx

Success Rate

6/12 ratings generated profit

Average Return

+5.08%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +5.08% per trade.

3 Months

xxx

Success Rate

6/12 ratings generated profit

Average Return

+10.82%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +10.82% per trade.

1 Year

Kaveri PohlmanClear Street

Success Rate

6/12 ratings generated profit

Average Return

+22.78%

reiterated a buy rating 15 days ago

Copying Kaveri Pohlman's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +22.78% per trade.

2 Years

xxx

Success Rate

8/26 ratings generated profit

Average Return

-9.97%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 30.77% of your transactions generating a profit, with an average return of -9.97% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CGEM Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CGEM has received 23 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CGEM average Analyst price target in the past 3 months is 26.33.

Each month's total comprises the sum of three months' worth of ratings.

CGEM Financial Forecast

CGEM Earnings Forecast

Next quarter’s earnings estimate for CGEM is -$0.95 with a range of -$1.22 to -$0.81. The previous quarter’s EPS was -$1.07. CGEM beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 51.30% of the time in the same period. In the last calendar year CGEM has Outperformed its overall industry.

No data currently available

CGEM Sales Forecast

Next quarter’s sales forecast for CGEM is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CGEM beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 45.99% of the time in the same period. In the last calendar year CGEM has Preformed in-line its overall industry.

CGEM Stock Forecast FAQ

What is CGEM’s average 12-month price target, according to analysts?

Based on analyst ratings, Cullinan Management’s 12-month average price target is 26.33.

What is CGEM’s upside potential, based on the analysts’ average price target?

Cullinan Management has 243.29% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CGEM a Buy, Sell or Hold?

Cullinan Management has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.

What is Cullinan Management’s price target?

The average price target for Cullinan Management is 26.33. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $34.00 ,the lowest forecast is $22.00. The average price target represents 243.29% Increase from the current price of $7.67.

What do analysts say about Cullinan Management?

Cullinan Management’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of CGEM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Cullinan Management (CGEM) Stock Forecast & Price Target

CGEM Analyst Ratings

CGEM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cullinan Management

CGEM Analyst Recommendation Trends

CGEM Financial Forecast

CGEM Earnings Forecast

CGEM Sales Forecast

CGEM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts